Orale Zusammensetzung mit Anorganischem Porösem Körper
Anmelder: Tanabe Pharma Corporation, Mitsubishi Chemical Corporation 🇯🇵
Details
- Veröffentlichungs-Nr.
- EP4736861
- Anmeldetag
- 26. Juni 2024
- Veröffentlichung
- 2. Januar 2025
- Rechtsraum
- EP
Abstract
The oral composition of the present disclosure includes an inorganic porous material, and with respect to choline and a primary, secondary, or tertiary amine or ammonia present as an equimolar mixture in simulated intestinal fluid, when 11.8 g of the inorganic porous material per 1 mmol of choline is mixed at a concentration of 2 g/L for 1 hour, the adsorption ratio of the primary, secondary, or tertiary amine or ammonia is 60.0% or more, and the adsorption ratio of choline is 40.0% or less. Alternatively, the oral composition of the present disclosure includes a zeolite, wherein the zeolite has an MFI structure and a molar ratio of SiO<2> to Al<2>O<3> of 30.0 or more and 130,000.0 or less, or the zeolite has a FER structure and a molar ratio of SiO<2> to Al<2>O<3> of 15.0 or more and 130,000.0 or less.
Anmelder
- Firmen
- Tanabe Pharma Corporation
Mitsubishi Chemical Corporation - Land
- 🇯🇵 Japan
Japanisches Chemieunternehmen mit Sitz in Tokio, Teil der Mitsubishi-Chemical-Gruppe. Das Unternehmen entwickelt Grund- und Spezialchemikalien, Kunststoffe, Materialien für Elektronik und Energiespeicher sowie Pharma- und Life-Science-Produkte.
2.926 Patente in unserer Datenbank